secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001724521-26-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer
--------------------------------------------------------------------------------

- Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.
- Casdatifan 100mg QD in late-line ccRCC: confirmed ORR 45.2%, median PFS 15.1 months (Jan 30, 2026 cut).
- Full-year 2026 GAAP revenue guidance $45-55M; R&D expenses expected to decrease meaningfully.
- Phase 3 PEAK-1 (casdatifan + cabozantinib) enrolling globally; 1L Phase 3 planned by end 2026.
- First inflammation program (oral MRGPRX2 antagonist) to enter clinic in 2026; oral TNF inhibitor in late 2026/early 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/0001724521-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000007/rcus-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001724521-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer